{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:28:12Z","timestamp":1793647692298,"version":"4.5.1"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012249","name":"Jiangxi University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["CXTD22003"],"award-info":[{"award-number":["CXTD22003"]}],"id":[{"id":"10.13039\/501100012249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012249","name":"Jiangxi University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["CXTD22001"],"award-info":[{"award-number":["CXTD22001"]}],"id":[{"id":"10.13039\/501100012249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011833","name":"Guangxi University of Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010857","name":"Jiangxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["20232ACB216016"],"award-info":[{"award-number":["20232ACB216016"]}],"id":[{"id":"10.13039\/501100010857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010857","name":"Jiangxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["20232BCJ22054"],"award-info":[{"award-number":["20232BCJ22054"]}],"id":[{"id":"10.13039\/501100010857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160663"],"award-info":[{"award-number":["82160663"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.bioorg.2024.107386","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T12:02:53Z","timestamp":1713441773000},"page":"107386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Research progress of PROTACs for neurodegenerative diseases therapy"],"prefix":"10.1016","volume":"147","author":[{"given":"Zhifang","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanying","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2024.107386_b0005","article-title":"Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases","volume":"10","author":"Erkkinen","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bioorg.2024.107386_b0010","unstructured":"United Nations Department of Economic and Social Affairs, Population Division (2020). World Population Ageing 2020 Highlights: Living arrangements of older persons (ST\/ESA\/SER.A\/451)."},{"key":"10.1016\/j.bioorg.2024.107386_b0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","article-title":"Prevalence estimates of amyloid abnormality across the alzheimer disease clinical spectrum","volume":"79","author":"Jansen","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bioorg.2024.107386_b0020","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s12640-022-00564-w","article-title":"CRISPR and iPSCs: Recent developments and future perspectives in neurodegenerative disease modelling research and therapeutics","volume":"40","author":"Sen","year":"2022","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.bioorg.2024.107386_b0025","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/B978-0-12-802395-2.00021-3","article-title":"Concepts and classification of neurodegenerative diseases","volume":"145","author":"Kovacs","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.bioorg.2024.107386_b0030","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","article-title":"Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases","volume":"10","author":"Soto","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bioorg.2024.107386_b0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41583-019-0240-3","article-title":"Amyloid-\u03b2-independent regulators of tau pathology in Alzheimer disease","volume":"21","author":"Kant","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bioorg.2024.107386_b0040","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41419-018-0963-5","article-title":"Bi-directional genetic modulation of GSK-3\u03b2 exacerbates hippocampal neuropathology in experimental status epilepticus","volume":"9","author":"Engel","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2024.107386_b0045","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2165\/00002512-200421100-00001","article-title":"Physiological roles of amyloid-beta and implications for its removal in Alzheimer's disease","volume":"21","author":"Bishop","year":"2004","journal-title":"Drugs Aging"},{"key":"10.1016\/j.bioorg.2024.107386_b0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1212\/CON.0000000000000819","article-title":"Synucleinopathies","volume":"26","author":"Coon","year":"2020","journal-title":"Continuum Lifelong Learning in Neurology"},{"key":"10.1016\/j.bioorg.2024.107386_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105652","article-title":"Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice","volume":"166","author":"Caron","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bioorg.2024.107386_b0060","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-021-01146-7","article-title":"Protein degradation technology: A strategic paradigm shift in drug discovery","volume":"14","author":"Li","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2024.107386_b0065","first-page":"934","article-title":"Targeted protein degradation: A promise for undruggable proteins, Cell","volume":"28","author":"Samarasinghe","year":"2021","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107386_b0070","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-1-0716-1665-9_8","article-title":"Kinetic detection of E3:PROTAC: Target ternary complexes using nanoBRET technology in live cells","volume":"2365","author":"Mahan","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bioorg.2024.107386_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114290","article-title":"The state of the art of PROTAC technologies for drug discovery","volume":"235","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107386_b0080","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","article-title":"Targeted protein degradation: elements of PROTAC design","volume":"50","author":"Paiva","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107386_b0085","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1021\/acs.jcim.8b00872","article-title":"In silico modeling of PROTAC-mediated ternary complexes: validation and application","volume":"59","author":"Drummond","year":"2019","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2024.107386_b0090","first-page":"1257","article-title":"Recent advances of degradation technologies based on PROTAC mechanism","volume":"12","author":"Xiao","year":"2022","journal-title":"Biomol. Ther."},{"key":"10.1016\/j.bioorg.2024.107386_b0095","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1111\/febs.15638","article-title":"Proteasome interaction with ubiquitinated substrates: From mechanisms to therapies, The","volume":"288","author":"Chen","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.bioorg.2024.107386_b0100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-1-0716-1665-9_5","article-title":"Mechanistic and structural features of PROTAC ternary complexes","volume":"2365","author":"Casement","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bioorg.2024.107386_b0105","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/2472555220965528","article-title":"E3 ligase ligands for PROTACs: how they were found and how to discover new ones","volume":"26","author":"Ishida","year":"2021","journal-title":"SLAS Discov."},{"key":"10.1016\/j.bioorg.2024.107386_b0110","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.3390\/molecules27196515","article-title":"Discovery of E3 ligase ligands for target protein degradation","volume":"27","author":"Lee","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2024.107386_b0115","doi-asserted-by":"crossref","first-page":"10141","DOI":"10.7150\/thno.46985","article-title":"The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination","volume":"10","author":"Jin","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2024.107386_b0120","article-title":"Light-controllable PROTACs for temporospatial control of protein degradation","volume":"9","author":"Liu","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2024.107386_b0125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-022-00999-9","article-title":"PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2024.107386_b0130","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.2019.37.7_suppl.259","article-title":"ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer","volume":"37","author":"Neklesa","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2024.107386_b0135","doi-asserted-by":"crossref","unstructured":"J. Flanagan, Y. Qian, S. Gough, M. Andreoli, M. Bookbinder, G. Cadelina, J. Bradley, E. Rousseau, R. R. Willard, J. Pizzano, C. Crews, A. Crew, I. Taylor, J. Houston, ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer, Cancer Res. 79 (2019) P5-04-18.","DOI":"10.1158\/1538-7445.SABCS18-P5-04-18"},{"key":"10.1016\/j.bioorg.2024.107386_b0140","unstructured":"Arvinas. Arvinas announces first-in-human dosing of ARV-102, an investigational PROTAC\u00ae protein degrader for neurodegenerative disease, https:\/\/ir.arvinas.com\/news-releases\/news-release-details\/arvinas-announces-first-human-dosing-arv-102-investigational."},{"key":"10.1016\/j.bioorg.2024.107386_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112186","article-title":"Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity","volume":"192","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107386_b0150","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1021\/acs.jmedchem.3c01007","article-title":"Discovery and preclinical pharmacology of NX-2127, an orally bioavailable degrader of Bruton's tyrosine kinase with immunomodulatory activity for the treatment of patients with B cell malignancies","volume":"67","author":"Robbins","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107386_b0155","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1038\/s41591-023-02635-7","article-title":"IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial","volume":"29","author":"Ackerman","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2024.107386_b0160","doi-asserted-by":"crossref","unstructured":"D. A. Stevens, R. Ewesuedo, A. McDonald, S. Agarwal, P. Henrick, R. Perea, A. Gollerkeri, J. Gollo, Phase 1 study of KT-413, a targeted protein degrader, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma, J. Clin. Oncol. 40 (2023) suppl. TPS3170.","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3170"},{"key":"10.1016\/j.bioorg.2024.107386_b0165","unstructured":"Nurix. NX-0479\/GS-6791 (IRAK4 degrader), https:\/\/www.nurixtx.com\/pipeline\/inflammation\/."},{"key":"10.1016\/j.bioorg.2024.107386_b0170","unstructured":"Kintor. The first patient was enrolled in the phase II clinical trial of AR-PROTAC (GT20029) for the treatment of alopecia in China, https:\/\/www.kintor.com.cn\/news\/295.html."},{"key":"10.1016\/j.bioorg.2024.107386_b0175","unstructured":"Cullgen. Cullgen announces first-in-human dose in phase I\/II trial of CG001419, a first-in-class TRK protein degrader for treatment of cancer patients, https:\/\/www.cullgen.com\/new-folder."},{"key":"10.1016\/j.bioorg.2024.107386_b0180","doi-asserted-by":"crossref","first-page":"CT128","DOI":"10.1158\/1538-7445.AM2023-CT128","article-title":"Abstract CT128: Phase 1 study of HSK29116, a Bruton tyrosine kinase (BTK) proteolysis-targeting chimera (PROTAC) agent, in patients with relapsed or refractory B-cell malignancies","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107386_b0185","unstructured":"Accutar Biotech. Accutar Biotechnology Announces First Patient Dosed in China with AC0176 in Phase 1 Study in Prostate Cancer, https:\/\/www.accutarbio.com\/news\/."},{"key":"10.1016\/j.bioorg.2024.107386_b0190","unstructured":"Accutar Biotech. Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in Phase 1 Study in ER-Positive Breast Cancer, https:\/\/www.accutarbio.com\/news\/."},{"key":"10.1016\/j.bioorg.2024.107386_b0195","doi-asserted-by":"crossref","first-page":"4_suppl","DOI":"10.1200\/JCO.2024.42.4_suppl.124","article-title":"Preliminary data from a dose-escalation phase 1 study with HP518, an AR PROTAC degrader: Safety, tolerability, pharmacokinetics (PK), and first assessment of anti-tumor activity in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Azad","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2024.107386_b0200","doi-asserted-by":"crossref","first-page":"12_Suppl","DOI":"10.1158\/1535-7163.TARG-23-A049","article-title":"Abstract A049: Investigation of FHD-609, a potent degrader of BRD9, in preclinical models of acute myeloid leukemia (AML)","volume":"22","author":"Dominici","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2024.107386_b0205","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2021-151125","article-title":"A first-in-class STAT3 degrader KT-333 in development for treatment of hematologic cancers","volume":"138","author":"Liu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2024.107386_b0210","doi-asserted-by":"crossref","first-page":"7_Suppl","DOI":"10.1158\/1538-7445.AM2023-ND03","article-title":"Discovery of ARV-766, an androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer","volume":"83","author":"Snyder","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107386_b0215","unstructured":"https:\/\/clinicaltrials.gov\/."},{"key":"10.1016\/j.bioorg.2024.107386_b0220","doi-asserted-by":"crossref","first-page":"e12330","DOI":"10.1002\/trc2.12330","article-title":"Challenges and progress in research diagnostics and therapeutics in Alzheimer's disease and related dementias","volume":"8","author":"Dokholyan","year":"2022","journal-title":"Alzheimers Dement (n y)."},{"key":"10.1016\/j.bioorg.2024.107386_b0225","first-page":"313","article-title":"The epidemiology of Alzheimer\u2019s disease modifiable risk factors and prevention","volume":"8","author":"Zhang","year":"2021","journal-title":"J. Prev Alzheimers Dis."},{"key":"10.1016\/j.bioorg.2024.107386_b0230","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40120-022-00335-x","article-title":"The humanistic and economic burden of Alzheimer's disease","volume":"11","author":"Monfared","year":"2022","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.bioorg.2024.107386_b0235","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5607\/en22004","article-title":"Physiological roles of monomeric amyloid-\u03b2 and implications for Alzheimer\u2019s disease therapeutics","volume":"31","author":"Jeong","year":"2022","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.bioorg.2024.107386_b0240","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.bioorg.2024.107386_b0245","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.3389\/fneur.2021.786353","article-title":"Tau ubiquitination in Alzheimer's disease","volume":"12","author":"Li","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.bioorg.2024.107386_b0250","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.3390\/ijms24076518","article-title":"Inflammatory processes in Alzheimer\u2019s disease-pathomechanism, diagnosis and treatment: A Review","volume":"24","author":"Twarowski","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107386_b0255","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jsps.2022.10.004","article-title":"An update on the novel and approved drugs for Alzheimer disease","volume":"30","author":"Alhazmi","year":"2022","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.bioorg.2024.107386_b0260","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.2174\/1389557522666220214092824","article-title":"Recent advancements in strategies for abnormal protein clearance in Alzheimer's disease","volume":"22","author":"Gong","year":"2022","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107386_b0265","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.neuroscience.2022.04.024","article-title":"Tau aggregation","volume":"518","author":"Hern\u00e1ndez","year":"2023","journal-title":"Neuroscience"},{"key":"10.1016\/j.bioorg.2024.107386_b0270","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.tins.2022.02.004","article-title":"Tau talk-synaptic and mitochondrial proteins interact with Tau in human neurons","volume":"45","author":"King","year":"2022","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.bioorg.2024.107386_b0275","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.brainresbull.2022.10.017","article-title":"Posttranscriptional regulation of neurofilament protein and tau in health and disease","volume":"192","author":"Yuan","year":"2022","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.bioorg.2024.107386_b0280","doi-asserted-by":"crossref","first-page":"eabl8809","DOI":"10.1126\/sciadv.abl8809","article-title":"Alzheimer\u2019s disease: ablating single master site abolishes tau hyperphosphorylation","volume":"8","author":"Stefanoska","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioorg.2024.107386_b0285","doi-asserted-by":"crossref","first-page":"12841","DOI":"10.3390\/ijms232112841","article-title":"Phosphorylated tau in Alzheimer\u2019s disease and other tauopathies","volume":"23","author":"Rawat","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107386_b0290","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1021\/jacs.2c11706","article-title":"Targeted dephosphorylation of tau by phosphorylation targeting chimeras (PhosTACs) as a therapeutic modality","volume":"145","author":"Hu","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2024.107386_b0295","first-page":"453","article-title":"Specific knockdown of endogenous tau protein by peptide-directed ubiquitin-proteasome degradation, Cell","volume":"23","author":"Chu","year":"2016","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107386_b0300","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejmech.2018.01.063","article-title":"Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway","volume":"146","author":"Lu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107386_b0305","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.7150\/thno.55680","article-title":"A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics."},{"key":"10.1016\/j.bioorg.2024.107386_b0310","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.801179","article-title":"Discovery and optimization of tau targeted protein degraders enabled by patient induced pluripotent stem cells-derived neuronal models of tauopathy","volume":"16","author":"Silva","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.bioorg.2024.107386_b0315","first-page":"699","article-title":"Treatment of Alzheimer\u2019s by PROTAC-tau protein degradation, ACS. Med","volume":"10","author":"Kargbo","year":"2019","journal-title":"Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107386_b0320","doi-asserted-by":"crossref","first-page":"26308","DOI":"10.1021\/acsomega.2c02130","article-title":"Design, synthesis, and bioactivity of novel bifunctional small molecules for Alzheimer\u2019s disease, ACS","volume":"7","author":"Liang","year":"2022","journal-title":"Omega"},{"key":"10.1016\/j.bioorg.2024.107386_b0325","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bbr.2017.11.015","article-title":"Diabetes mellitus and Alzheimer\u2019s disease: GSK-3\u03b2 as a potential link","volume":"339","author":"Zhang","year":"2018","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bioorg.2024.107386_b0330","article-title":"GSK-3\u03b2 in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer","volume":"1867","author":"Lin","year":"2020","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bioorg.2024.107386_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109525","article-title":"An inhibitor with GSK3\u03b2 and DYRK1A dual inhibitory properties reduces Tau hyperphosphorylation and ameliorates disease in models of Alzheimer's disease","volume":"232","author":"Liu","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bioorg.2024.107386_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112949","article-title":"PROTACs suppression of GSK-3\u03b2, a crucial kinase in neurodegenerative diseases","volume":"210","author":"Jiang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107386_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113889","article-title":"Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease","volume":"226","author":"Qu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107386_b0350","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1021\/acschemneuro.3c00096","article-title":"PROTAC-induced glycogen synthase kinase 3\u03b2 degradation as a potential therapeutic strategy for Alzheimer's disease","volume":"14","author":"Guardigni","year":"2023","journal-title":"ACS Chem. Nerosci."},{"issue":"suppl 2","key":"10.1016\/j.bioorg.2024.107386_b0355","article-title":"Depression and progression of motor symptoms in early stage of Parkinson's disease","volume":"37","author":"Hwang","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bioorg.2024.107386_b0360","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.973310","article-title":"The long-term trend of Parkinson\u2019s disease incidence and mortality in China and a Bayesian projection from 2020 to 2030","volume":"14","author":"Chen","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bioorg.2024.107386_b0365","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-pathmechdis-031521-034145","article-title":"Genetics and pathogenesis of Parkinson's syndrome","volume":"18","author":"Ye","year":"2023","journal-title":"Annu. Rev. Pathol."},{"issue":"S1","key":"10.1016\/j.bioorg.2024.107386_b0370","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.3233\/JPD-223176","article-title":"Immunogenetic determinants of Parkinson\u2019s disease etiology","volume":"12","author":"Kung","year":"2022","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.bioorg.2024.107386_b0375","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer\u2019s disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bioorg.2024.107386_b0380","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41531-021-00210-w","article-title":"\u03b1-Synuclein-induced dysregulation of neuronal activity contributes to murine dopamine neuron vulnerability","volume":"7","author":"Dagra","year":"2021","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.bioorg.2024.107386_b0385","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/mds.28863","article-title":"Increased stroke risk in patients with Parkinson's disease with LRRK2 mutations","volume":"37","author":"Mac\u00edas-Garc\u00eda","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bioorg.2024.107386_b0390","first-page":"222","article-title":"A review on Parkinson\u2019s disease treatment","volume":"8","author":"Lee","year":"2021","journal-title":"Neurosciences"},{"key":"10.1016\/j.bioorg.2024.107386_b0395","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nan.12298","article-title":"Review: Sporadic Parkinson's disease: development and distribution of \u03b1-synuclein pathology","volume":"42","author":"Tredici","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.bioorg.2024.107386_b0400","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13578-021-00709-y","article-title":"\u03b1-Synuclein-mediated neurodegeneration in Dementia with Lewy bodies: the pathobiology of a paradox","volume":"11","author":"Simon","year":"2021","journal-title":"Cell Biosci."},{"key":"10.1016\/j.bioorg.2024.107386_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2022.102270","article-title":"Amyloid \u03b2, Tau, and \u03b1-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases","volume":"214","author":"Sengupta","year":"2022","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bioorg.2024.107386_b0410","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3390\/cells11111732","article-title":"Alpha-synuclein aggregation pathway in Parkinson's disease: current status and novel therapeutic approaches","volume":"11","author":"Vidovi\u0107","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2024.107386_b0415","article-title":"Proteolysis targeting chimeric (PROTAC) compound with E3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurovegetative diseases","author":"Crew","year":"2020","journal-title":"WO2020041331"},{"key":"10.1016\/j.bioorg.2024.107386_b0420","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1021\/acs.jmedchem.3c00274","article-title":"Discovery of Small-Molecule Degraders for Alpha-Synuclein Aggregates","volume":"66","author":"Tong","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107386_b0425","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.3390\/molecules28114458","article-title":"Design, synthesis and biological evaluation of \u03b1-synuclein proteolysis-targeting chimeras","volume":"28","author":"Wen","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2024.107386_b0430","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1093\/hmg\/ddz245","article-title":"Physiological and pathological roles of LRRK2 in the nuclear envelope integrity","volume":"28","author":"Shani","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bioorg.2024.107386_b0435","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1042\/EBC20210013","article-title":"LRRK2 signaling in neurodegeneration: two decades of progress","volume":"65","author":"Iannotta","year":"2021","journal-title":"Essays Biochem."},{"key":"10.1016\/j.bioorg.2024.107386_b0440","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1042\/BST20160264","article-title":"Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation","volume":"45","author":"Islam","year":"2017","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bioorg.2024.107386_b0445","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3390\/biom11081101","article-title":"LRRK2 Targeting strategies as potential treatment of Parkinson's disease","volume":"11","author":"Wojewska","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2024.107386_b0450","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cmdc.202000872","article-title":"The tale of proteolysis targeting chimeras","volume":"16","author":"Konstantinidou","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2024.107386_b0455","doi-asserted-by":"crossref","first-page":"16930","DOI":"10.1021\/jacs.2c05499","volume":"144","author":"Liu","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2024.107386_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129449","article-title":"Development of a highly potent and selective degrader of LRRK2","volume":"94","author":"Hatcher","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107386_b0465","unstructured":"N. S. Gray, J. Hatcher, Degraders of wild-type and mutant forms of LRRK2, WO2020081682, 2020."},{"key":"10.1016\/j.bioorg.2024.107386_b0470","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000524732","article-title":"Epidemiology of Huntington\u2019s disease in the United States medicare and medicaid populations","volume":"56","author":"Exuzides","year":"2022","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.bioorg.2024.107386_b0475","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00415-018-8940-6","article-title":"Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration","volume":"266","author":"Podvin","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.bioorg.2024.107386_b0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-170235","article-title":"Is Huntingtin dispensable in the adult brain","volume":"6","author":"Liu","year":"2017","journal-title":"J. Huntingtons Dis."},{"key":"10.1016\/j.bioorg.2024.107386_b0485","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.molcel.2018.07.032","article-title":"mHTT seeding activity: a marker of disease progression and neurotoxicity in models of Huntington's disease","volume":"71","author":"Ast","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2024.107386_b0490","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3390\/biomedicines10061432","article-title":"Molecular pathophysiological mechanisms in Huntington's disease","volume":"10","author":"Jurcau","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2024.107386_b0495","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.3390\/biomedicines10081895","article-title":"Therapeutic strategies in Huntington's disease: from genetic defect to gene therapy","volume":"10","author":"Jurcau","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2024.107386_b0500","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jnc.14853","article-title":"The pathobiology of perturbed mutant huntingtin protein-protein interactions in Huntington's disease","volume":"151","author":"Wanker","year":"2019","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bioorg.2024.107386_b0505","doi-asserted-by":"crossref","first-page":"1107323","DOI":"10.3389\/fmolb.2023.1107323","article-title":"Ubiquitin-modifying enzymes in Huntington's disease","volume":"10","author":"Sap","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bioorg.2024.107386_b0510","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024257","article-title":"Prion-like characteristics of polyglutamine-containing proteins","volume":"8","author":"Pearce","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bioorg.2024.107386_b0515","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1128\/MCB.24.18.8195-8209.2004","article-title":"Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro","volume":"24","author":"Trushina","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2024.107386_b0520","doi-asserted-by":"crossref","first-page":"11530","DOI":"10.1002\/anie.201706529","article-title":"Discovery of small molecules that induce the degradation of Huntingtin","volume":"56","author":"Tomoshige","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bioorg.2024.107386_b0525","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bmcl.2018.01.012","article-title":"Degradation of huntingtin mediated by a hybrid molecule composed of IAP antagonist linked to phenyldiazenyl benzothiazole derivative","volume":"28","author":"Tomoshige","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107386_b0530","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/539179a","article-title":"Neurodegenerative diseases","volume":"539","author":"Heemels","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2024.107386_b0535","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-981-19-7376-5_3","article-title":"Inflammation-mediated responses in the development of neurodegenerative diseases","volume":"1411","author":"Nainu","year":"2023","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.bioorg.2024.107386_b0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpc.2023.106972","article-title":"Shapeshifter TDP-43: Molecular mechanism of structural polymorphism, aggregation, phase separation and their modulators","volume":"295","author":"Doke","year":"2023","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.bioorg.2024.107386_b0545","doi-asserted-by":"crossref","first-page":"e2200410","DOI":"10.1002\/pmic.202200410","article-title":"Proteomics elucidating physiological and pathological functions of TDP-43","volume":"23\u201324","author":"Morato","year":"2023","journal-title":"Proteomics"},{"key":"10.1016\/j.bioorg.2024.107386_b0550","doi-asserted-by":"crossref","first-page":"12508","DOI":"10.3390\/ijms232012508","article-title":"Molecular dissection of TDP-43 as a leading cause of ALS\/FTLD","volume":"23","author":"Tamaki","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107386_b0555","doi-asserted-by":"crossref","first-page":"15755","DOI":"10.3390\/ijms232415755","article-title":"TDP-43 proteinopathy and tauopathy: do they have pathomechanistic links?","volume":"23","author":"Riku","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107386_b0560","doi-asserted-by":"crossref","first-page":"e12778","DOI":"10.1111\/nan.12778","article-title":"Concurrent tau pathologies in frontotemporal lobar degeneration with TDP-43 pathology","volume":"48","author":"Koga","year":"2022","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.bioorg.2024.107386_b0565","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40035-022-00331-z","article-title":"TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis","volume":"11","author":"L\u00e9pine","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.bioorg.2024.107386_b0570","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12929-023-00921-7","article-title":"Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera","volume":"30","author":"Tseng","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.bioorg.2024.107386_b0575","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3892\/mmr.2022.12586","article-title":"Activation of neurotrophin signalling with light-inducible receptor tyrosine kinases","volume":"25","author":"Zhang","year":"2022","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bioorg.2024.107386_b0580","doi-asserted-by":"crossref","unstructured":"A Amatu, A Sartore-Bianchi, K Bencardino, E G Pizzutilo, F Tosi, S Siena, Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer, Ann. Oncol. 30 (Suppl_8) (2019) viii5\u2013viii15.","DOI":"10.1093\/annonc\/mdz383"},{"key":"10.1016\/j.bioorg.2024.107386_b0585","doi-asserted-by":"crossref","first-page":"14562","DOI":"10.1021\/acs.jmedchem.0c01342","article-title":"Discovery of first-in-class potent and selective tropomyosin receptor kinase degraders","volume":"63","author":"Chen","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107386_b0590","article-title":"Tropomyosin Receptor Kinase (TRK)","volume":"WO2020038415","author":"Liu","year":"2020","journal-title":"Degradation Compounds and Methods of Use"},{"key":"10.1016\/j.bioorg.2024.107386_b0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102461","article-title":"IRAK family in inflammatory autoimmune diseases","volume":"19","author":"Su","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bioorg.2024.107386_b0600","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MOH.0000000000000693","article-title":"IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies","volume":"29","author":"Bennett","year":"2022","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.bioorg.2024.107386_b0605","first-page":"1081","article-title":"Targeting IRAK4 for degradation with PROTACs, ACS. Med","volume":"10","author":"Nunes","year":"2019","journal-title":"Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107386_b0610","first-page":"1251","article-title":"PROTAC degradation of IRAK4 for the treatment of neurodegenerative and cardiovascular diseases, ACS. Med","volume":"10","author":"Kargbo","year":"2019","journal-title":"Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107386_b0615","first-page":"1370","article-title":"PROTAC degradation of IRAK4 for the treatment of cancer, ACS. Med","volume":"10","author":"Kargbo","year":"2019","journal-title":"Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107386_b0620","first-page":"82","article-title":"Design, synthesis, and biological evaluation of IRAK4-targeting PROTACs, ACS. Med","volume":"12","author":"Chen","year":"2021","journal-title":"Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107386_b0625","first-page":"1","article-title":"Protein degradation technology: a strategic paradigm shift in drug discovery","volume":"14","author":"Haobin Li","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2024.107386_b0630","first-page":"25","article-title":"Induced degradation of proteins by PROTACs and other strategies: towards promising drugs","volume":"215","author":"Mich\u00e8le","year":"2021","journal-title":"Biol Aujourdhui"},{"key":"10.1016\/j.bioorg.2024.107386_b0635","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1080\/14756366.2022.2076675","article-title":"Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges","volume":"37","author":"Wang","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107386_b0640","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","article-title":"Crews Targeted protein degradation: elements of PROTAC design","volume":"50","author":"Paiva","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107386_b0645","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.685106","article-title":"Opportunities and challenges of small molecule induced targeted protein degradation","volume":"9","author":"He","year":"2021","journal-title":"Front. Cell Dev. Biol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824002918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824002918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T05:02:00Z","timestamp":1715662920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824002918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":129,"alternative-id":["S0045206824002918"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107386","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research progress of PROTACs for neurodegenerative diseases therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107386","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107386"}}